dc.contributor.author | Porcuna, Jesús | |
dc.contributor.author | Menéndez-Gutiérrez, María Piedad | |
dc.contributor.author | Ricote, Mercedes | |
dc.date.accessioned | 2020-06-09T14:26:56Z | |
dc.date.available | 2020-06-09T14:26:56Z | |
dc.date.issued | 2020-05-08 | |
dc.identifier.citation | Curr Opin Pharmacol. 2020; 53:27-34 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/10308 | |
dc.description.abstract | Macrophages are key immune cells that reside in almost all tissues of the body, where they exert pleiotropic functions in homeostasis and disease. Development and identity of macrophages in each organ are governed by tissue-dependent signaling pathways and transcription factors that ultimately define specific tissue-resident macrophage phenotypes and functions. In recent years, nuclear receptors, a class of ligand-activated transcription factors, have been found to play important roles in macrophage specification in several tissues. Nuclear receptors are thus important targets for therapies aimed at controlling the numbers and functions of tissue-resident macrophages. This review outlines current knowledge about the critical roles of nuclear receptors in tissue-resident macrophage development, specification, and maintenance. | es_ES |
dc.description.sponsorship | This work was supported by grants from the Spanish Ministerio de Ciencia e Innovacion (MCI) (SAF2017-90604-REDT-NurCaMein, RTI2018-095928-BI00), La Marato de TV3 Foundation (201605-32), and the Comunidad de Madrid (MOIRB2017/BMD-3684) to M.R, and the Formacion de Profesorado Universitario (FPU17/01731) program (MCI) to J.P. The CNIC is supported by the MCI and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (SEV-2015-0505). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.relation.isversionof | Postprint | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Molecular control of tissue-resident macrophage identity by nuclear receptors. | es_ES |
dc.type | Artículo | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 32403022 | es_ES |
dc.format.volume | 53 | es_ES |
dc.format.page | 27-34 | es_ES |
dc.identifier.doi | 10.1016/j.coph.2020.04.001 | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | |
dc.contributor.funder | Fundació La Marató | |
dc.contributor.funder | Comunidad de Madrid | |
dc.contributor.funder | Fundación ProCNIC | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1471-4973 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.coph.2020.04.001 | es_ES |
dc.identifier.journal | Current opinion in pharmacology | es_ES |
dc.repisalud.orgCNIC | CNIC::Grupos de investigación::Señalización de los Receptores Nucleares | es_ES |
dc.repisalud.institucion | CNIC | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/SEV-2015-0505 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/SAF2017-90604-REDT-NurCaMein | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/RTI2018-095928-BI00 | es_ES |
dc.rights.accessRights | info:eu-repo/semantics/embargoedAccess | es_ES |